Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Miroslav S. Ravic | M | 75 |
MGB Biopharma Ltd.
 MGB Biopharma Ltd. BiotechnologyHealth Technology MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom. | 14 jaar |
| Raymond J. Spencer | M | - |
MGB Biopharma Ltd.
MGB Biopharma Ltd. BiotechnologyHealth Technology MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom. | - |
| Adam Christie | M | - |
MGB Biopharma Ltd.
MGB Biopharma Ltd. BiotechnologyHealth Technology MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom. | - |
| John Waddell | M | 68 |
MGB Biopharma Ltd.
MGB Biopharma Ltd. BiotechnologyHealth Technology MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom. | - |
| Steve Felstead | M | 65 |
MGB Biopharma Ltd.
MGB Biopharma Ltd. BiotechnologyHealth Technology MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom. | - |
| Christopher Thomas Wardhaugh | M | 54 |
MGB Biopharma Ltd.
MGB Biopharma Ltd. BiotechnologyHealth Technology MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom. | 5 jaar |
| Ken Fyvie | M | - |
MGB Biopharma Ltd.
MGB Biopharma Ltd. BiotechnologyHealth Technology MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom. | 8 jaar |
| Stephanie Dancer | F | - |
MGB Biopharma Ltd.
MGB Biopharma Ltd. BiotechnologyHealth Technology MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom. | - |
| Curtis Gemmell | M | - |
MGB Biopharma Ltd.
MGB Biopharma Ltd. BiotechnologyHealth Technology MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigd Koninkrijk | 9 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Colin Suckling
- Persoonlijk netwerk
